8
NEWS
Heinemann
heads to Afon
Afon Technology has announced
the appointment of Professor Lutz
Heinemann as the newest member
of its Clinical Advisory Board.
In 1999, Professor Heinemann
founded the clinical research
organisation Profil Institut für
Stoffwechselforschung in Neuss,
Germany. He is currently the
Managing Editor of the Journal of
Diabetes Science and Technology,
as well as a member of national and
international diabetes associations.
Afon Technology's CEO Sabih
Chaudhry expects Heinemann
to bring his wealth of scientific
knowledge to the Welsh tech
company, which is developing the
world's first non-invasive wearable
blood glucose sensor, saying ""We
are thrilled to welcome Professor
Heinemann to Afon Technology's
Clinical Advisory Board. As a
renowned international diabetes
expert, he brings a wealth of
scientific knowledge that perfectly
aligns with our vision of creating
the world's first non-invasive
wearable blood glucose sensor."
IDDT news
The latest IDDT Newsletters are
now available on its website. The
June 2023 Newsletter includes
articles on: Does insulin make you
fat?; Stigma and bias still exist!;
Dry eye - symptoms, treatment
and prevention. To view it,
CLICK HERE.
Type 2 & You
The June 2023 issue of Type 2 &
You includes articles on why oral
health is important, how to read
food nutrition labels, and diabetes
and UTIs (urinary tract infections).
To read it, CLICK HERE.
Longer T2D survival
New research has found that treatment with metformin is significantly
linked with reduced mortality in people with Type 2 diabetes, compared with
treatment with other anti-diabetes drug classes. Treatment with a sodiumglucose
cotransporter 2 inhibitor (SGLT2i) was also found to be significantly
associated with increased longevity, compared with treatment with other
glucose-lowering medications. The survival of people with Type 2 diabetes on
SGLT2i treatment approximated that of people without diabetes, and SGLT2i
treatment was also linked with significantly lower cancer-related mortality.
These results should encourage clinicians to consider metformin and an
SGLT2i agent for either single- or dual-drug first-line treatment of people
with Type 2 diabetes.
To read more, CLICK HERE.
Insulin awareness week
Innovative ways to promote insulin
safety across University Hospital
Southampton were showcased during
a special visit to mark a national
diabetes campaign. Insulin Safety
Week (ISW) took place in the UK and
Ireland, aiming to raise awareness in
a bid to reduce insulin errors among
healthcare professionals. The national
campaign built on interest generated
by successful local campaigns
across the country, including in
Leicester, Hastings, Eastbourne
and Southampton. The project was
funded by Sanofi which had no input
into any arrangement or content.
Jessamy Baird, Country Lead and
Head of General Medicines for Sanofi
in the UK and Ireland, met with both
the Trust's CEO David French and
Lead Inpatient Diabetes Specialist
Nurse Paula Johnston at University
Hospital Southampton to discuss
what activities were taking place
at the hospital during ISW. On the
visit, Jessamy watched the hospital's
diabetes team spread the crucial
insulin safety message in an engaging
way with particular focus on the
timings and types of insulin available.
Dedicated NHS Diabetes Advice helpline
0345 123 2399